[Chemotherapy with fosfomycin, cefoxitin, and cefotaxime in experimental E. coli-pleuropneumonia (author's transl)].
Two models of pneumonia--the experimental E. coli-pleuropneumonia and "intrapulmonary" E. coli-pneumonia--were employed in these studies. Only fosfomycin was effective in both models even at the low dosage of 100 mg/kg/d. The comparative drugs cefotaxime and cefoxitin, however, were not able to reduce the bacteria in both lungs even at very high dosages of 900 mg/kg and 300 mg/kg per day respectively over 6 days.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002439:Cefotaxime; D002440:Cefoxitin / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004927:Escherichia coli Infections; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D007700:Kinetics; D011001:Pleuropneumonia / Q000188:drug therapy*; D051381:Rats
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005578:Fosfomycin; D002440:Cefoxitin; D002439:Cefotaxime
Therapieergebnisse mit Fosfomycin, Cefoxitin und Cefotaxim an experimenteller E. coli-Pleuropneumonie.